Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis

Translational Neurodegeneration

Xulong Ding¹  Peng Lei¹  Shuting Zhang²  Lu Wang³  Lijun Jiang⁴  Tao Li⁴ 

[1] Department of Neurology and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, 610041, Chengdu, China;Department of Neurology, West China Hospital, Sichuan University, 610041, Chengdu, China;Department of Rehabilitation Medicine, West China Hospital, Sichuan University, 610041, Chengdu, China;Mental Health Center and West China Brain Research Center, West China Hospital, Sichuan University, 610041, Chengdu, China;

关键词: Tau;    Phosphorylated tau 181;    Alzheimer’s disease;    Simoa;    IMR;    EIMAF/a-EIMAF;    MSD;    Plasma biomarker;   

DOI  :  10.1186/s40035-021-00234-5

来源: Springer

【 摘 要 】

A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer’s disease (AD). Recent advancement in ultrasensitive protein assays has allowed the quantification of tau and phosphorylated tau proteins in peripheral plasma. Here we identified 66 eligible studies reporting quantification of plasma tau and phosphorylated tau 181 (ptau181) using four ultrasensitive methods. Meta-analysis of these studies confirmed that the AD patients had significantly higher plasma tau and ptau181 levels compared with controls, and that the plasma tau and ptau181 could predict AD with high-accuracy area under curve of the Receiver Operating Characteristic. Therefore, plasma tau and plasma ptau181 can be considered as biomarkers for AD diagnosis.

【 授权许可】

CC BY